CompletedEUCTR 2010-023007-10
A neuroscience perspective on anxiety proneness - Sex differences, monoaminergic pathways and treatment response
This historical record does not confirm current site availability.
Historical research recordAges 18+Sweden
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
Who was this study for?
Listed age limits: from 18 years.
- Listed locations
- Sweden
- Compensation
- Payment and expense reimbursement have not been verified.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- Not clearly listed
- Sponsor
- Uppsala university
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Sweden
- Age range
- Over 18 Years
- Official registry ID
- EUCTR 2010-023007-10
- Official title
Show the full official title
A neuroscience perspective on anxiety proneness - Sex differences, monoaminergic pathways and treatment response
Recruitment & locations
CompletedSweden
Registry details
Historical country statuses
- Sweden — Completed
Questions about this study
Who is behind this study?
The study sponsor is Uppsala university, a university.
Who was this study for?
Listed age limits: from 18 years.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
CompletedNCT05729373
A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder
Researchers compared SEP-363856 and placebo to find out how the approaches affected anxiety symptoms in adults with an anxiety condition.
CompletedEUCTR 2004-001500-13
An 8-week, multicentre, randomised, double-blind, placebo-controlled, flexible dose study of Pregabalin (300-600 mg/day) and Venlafaxine XR (75-225 mg/day) for the acute treatment of DSM-IV General...
United Kingdom, Ireland, Italy, + 2 others
CompletedEUCTR 2005-003181-41
An eight-week, double-blind, placebo-controlled, multicenter study with paroxetine (20 mg q24) as positive control, evaluating the efficacy, safety and tolerability of a fixed dose of SR58611A (350...
Austria, Estonia, Sweden